KPW
AUPH icon

Kore Private Wealth’s Aurinia Pharmaceuticals AUPH Stock Holding History

Kore Private Wealth’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,000
Closed -$32K – 332
2020
Q2 		$32K Hold
2,000
– – 0.01% 554
2020
Q1 		$29K Hold
2,000
– – 0.01% 525
2019
Q4 		$41K Buy
+2,000
New +$18.4K 0.01% 510
2019
Q2 		– Sell
-2,000
Closed -$13K – 271
2019
Q1 		$13K Buy
+2,000
New +$13.3K ﹤0.01% 562

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Kore Private Wealth's AUPH Position: Q3 2020 in Review

Kore Private Wealth sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2020, closing a stake of 2,000 shares — an estimated $32K sold.

Kore Private Wealth first reported a position in AUPH in Q1 2019 and held it in 4 quarters. The position peaked at $41K in Q4 2019. 145 funds tracked by Wall St. Rank hold AUPH as of Q3 2020.

  • Kore Private Wealth reported no remaining Aurinia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 2,000 Aurinia Pharmaceuticals shares in Q3 2020, an estimated $32K.
  • Kore Private Wealth first reported a position in Aurinia Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • Kore Private Wealth's Aurinia Pharmaceuticals position peaked at $41K in Q4 2019.
  • 145 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.